|
|
News Breaks | | | | September 18, 2012 | | 11:16 EDT |  | NYMX | Nymox reports safety monitoring committee results for BPH repeat injection study
Nymox Pharmaceutical announced positive results of a recent Safety Monitoring Committee review of safety data from the Company's Phase 3 NX02-0020 repeat injection U.S. study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The Safety Monitoring Committee review was favorable and indicated no significant safety concerns for the trial to date. Patient recruitment for the trial is complete with top-line efficacy results expected near the end of this year. The NX02-0020 trial was initiated in mid-2011, and completed enrollment in June 2012. The study is an open label study of the safety and efficacy of repeat injection of the drug involving 200 men who had previously participated in an NX-1207 clinical trial for BPH. | |
|
News For NYMX From The Last 14 Days Check below for free stories on NYMX the last two weeks. |
|
|
| May 15, 2013 | | 09:46 EDT |  | NYMX | Nymox reports Q1 EPS (3c), consensus (5c)
 Subscribe for More Information | |
|
|
|
|
|
|
